Search This Blog

Tuesday, September 1, 2026

Telix aligns with FDA on NDA path for reimbursed 68Ga-PSMA-PET imaging in pre-biopsy prostate cancer

 

Telix aligns with FDA on NDA pathway for reimbursed 68Ga-PSMA-PET imaging in pre-biopsy prostate cancer using Illuccix and Gozellix

  • Company has completed enrollment of 350 patients in its Phase 3 BiPASS study of Illuccix and Gozellix.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)